Mineralys Therapeutics Inc. held its annual meeting of stockholders on May 22, 2025. The stockholders voted on two key proposals during the meeting. The first proposal was to elect two directors, Glenn P. Sblendorio and Derek DiRocco, Ph.D., as Class II directors. The second proposal was to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Both proposals were approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.